Patents by Inventor Yoshiki Sawa

Yoshiki Sawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220372437
    Abstract: A method for producing a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel, the method comprising: a step 1 of applying a fibrinogen solution containing at least one selected from the group consisting of cells and drugs and fibrinogen dropwise onto a surface of a substrate made of a gelatin hydrogel; a step 2 of adding thrombin to the fibrinogen solution on the surface of the substrate; a step 3 of placing a support film on and in contact with a top surface of the fibrinogen solution to which the thrombin has been added; a step 4 of forming a fibrin sheet containing the at least one selected from the group consisting of cells and drugs in a fibrin gel between the substrate and the support film by a reaction between the fibrinogen and the thrombin; and a step 5 of melting the substrate at a temperature not lower than a melting temperature of the gelatin hydrogel to separate, from the substrate, the fibrin sheet supported by the support film.
    Type: Application
    Filed: September 9, 2020
    Publication date: November 24, 2022
    Applicant: OSAKA UNIVERSITY
    Inventors: Takaaki SAMURA, Shigeru MIYAGAWA, Yoshiki SAWA, Junya YOKOYAMA
  • Publication number: 20220323726
    Abstract: To provide a catheter for aortic valvuloplasty in which it is possible to significantly increase the therapeutic effect despite being minimally invasive. The present invention provides a catheter for aortic valvuloplasty characterized by including: first to third balloons that can expand and contract due to supply of a fluid, it being possible to change the relative positional relationships of the first to third balloons; first to third shafts that connect to the first to third balloons at the tip and supply fluid to the first to third balloons to cause the first to third balloons to expand and contract independently of each other; and at least one wire that introduces the first to third balloons from outside the patient's body to the aortic valve.
    Type: Application
    Filed: September 8, 2020
    Publication date: October 13, 2022
    Applicant: OSAKA UNIVERSITY
    Inventors: Yoshiki Sawa, Masakazu Yagi, Yusuke Misumi
  • Patent number: 11441115
    Abstract: When detachment of a cell sheet from a culture dish has started at an unintended timing, immediately detach the cell sheet from the culture dish while preventing generation of wrinkles and the like in the cell sheet. A cell culture device captures an image of cells in the culture dish, and controls a cooling mechanism and a shaking mechanism based on the image so as to shake the cells while cooling them.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: September 13, 2022
    Assignees: DAI NIPPON PRINTING CO., LTD., OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHA
    Inventors: Taro Nagai, Yoshiki Sawa, Shigeru Miyagawa, Kenji Oyama
  • Publication number: 20220272963
    Abstract: A cell cryopreservation method including adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid.
    Type: Application
    Filed: May 19, 2022
    Publication date: September 1, 2022
    Inventors: Asuka Nogami, Motoki Tatsumi, Nanase Ishii, Mizuyuki Ryu, Yoshihiko Hirata, Yoshiki Sawa, Shigeru Miyagawa, Atsuhiro Saito, Hirotatsu Ohkawara
  • Publication number: 20220249613
    Abstract: Cell cultures for treating peripheral arterial disease, methods for producing the cell cultures and methods for treating peripheral arterial disease using the cell cultures are provided. The cell cultures may be 100 to 500 ?m in size and may possess an extracellular matrix on an outer surface of the cell culture, and the like are provided.
    Type: Application
    Filed: May 2, 2022
    Publication date: August 11, 2022
    Applicants: OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHA
    Inventors: Yoshiki SAWA, Shigeru MIYAGAWA, Keisuke MIYAKE, Kenji OYAMA
  • Publication number: 20220142507
    Abstract: A heart failure diagnostic device includes a piezoelectric sensor sheet having flexibility and configured to output a detection signal corresponding to an input vibration. A respiratory signal acquisition unit is configured to extract, as a respiratory signal, a signal of a vibration frequency caused by respiration from the detection signal detected by the piezoelectric sensor sheet. A power spectrum calculator is configured to obtain a power spectrum of a respiratory frequency band from the respiratory signal, and a signal corrector is configured to correct the detection signal such that in the power spectrum, a maximum value of a first-order frequency component of a respiratory waveform is not smaller than 1.5 times a maximum value of a second-order frequency component of the respiratory waveform to obtain the respiratory signal.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Inventors: Wataru TAKAHASHI, Masanori YAMAMOTO, Atsuki SHIMIZU, Mitsuyoshi KONDO, Jun Taguchi, Hidetsugu ASANOI, Yoshiki SAWA, Shigeru MIYAGAWA
  • Publication number: 20210388320
    Abstract: Provided is a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, wherein the content ratio of undifferentiated pluripotent stem cells is 0.2% or less.
    Type: Application
    Filed: July 28, 2021
    Publication date: December 16, 2021
    Inventors: Shigeo Masuda, Nagako Sougawa, Satsuki Fukushima, Shigeru Miyagawa, Yoshiki Sawa
  • Patent number: 11124770
    Abstract: A sheet-shaped cell culture is disclosed that includes myocardial cells derived from pluripotent stem cells and has excellent functional properties. A sheet-shaped cell culture obtained by culturing a cell population that includes myocardial cells derived from pluripotent stem cells, wherein the proportion of the number of the myocardial cells derived from pluripotent stem cells to the total number of cells in the cell population is 50% to 70%; a method of producing the sheet-shaped cell culture; a composition including the sheet-shaped cell culture; and a method of treating a disease using the sheet-shaped cell culture or the composition.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: September 21, 2021
    Assignees: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITY
    Inventors: Hiroko Iseoka, Yoshiki Sawa, Shigeru Miyagawa, Satsuki Fukushima
  • Publication number: 20210187031
    Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.
    Type: Application
    Filed: January 18, 2017
    Publication date: June 24, 2021
    Applicant: OSAKA UNIVERSITY
    Inventors: Daisuke KAJITA, Satsuki FUKUSHIMA, Shigeru MIYAGAWA, Yoshiki SAWA
  • Patent number: 10995211
    Abstract: An oxygen-absorbing resin composition containing an ethylene terephthalate type polyester resin and an organic oxygen absorber and, further, containing cobalt in an amount of 5 to 50 ppm and titanium in an amount of 1 to 15 ppm calculated as elements.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: May 4, 2021
    Assignee: TOYO SEIKAN GROUP HOLDINGS, LTD.
    Inventors: Yoshiki Sawa, Toshiki Yamada, Yukiko Hirayama, Kanna Muramatsu
  • Publication number: 20210113464
    Abstract: The present invention provides a clinically applicable, safe and convenient, pharmaceutical composition for disease site-specific treatment. The pharmaceutical composition for disease site-specific treatment comprises a stealth liposome having a prostaglandin I2 receptor agonist encapsulated therein.
    Type: Application
    Filed: November 27, 2017
    Publication date: April 22, 2021
    Inventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
  • Publication number: 20210009934
    Abstract: When detachment of a cell sheet from a culture dish has started at an unintended timing, immediately detach the cell sheet from the culture dish while preventing generation of wrinkles and the like in the cell sheet. A cell culture device captures an image of cells in the culture dish, and controls a cooling mechanism and a shaking mechanism based on the image so as to shake the cells while cooling them.
    Type: Application
    Filed: March 12, 2019
    Publication date: January 14, 2021
    Applicants: DAI NIPPON PRINTING CO., LTD., OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHA
    Inventors: Taro NAGAI, Yoshiki SAWA, Shigeru MIYAGAWA, Kenji OYAMA
  • Publication number: 20200392466
    Abstract: Disclosed is a method for producing a high-quality graft from pluripotent stem cell-derived differentiation-induced cells, a graft produced by using the method, and a method for treating a disease using the graft are described Embodiments of a method for producing a graft are described, which include a step of performing an operation for removing undifferentiated cells in a cell population containing pluripotent stem cell-derived differentiation-induced cells, optionally a step of freezing the cell population and thereafter thawing the cell population, and a step of seeding the obtained cell population on a culture substrate and performing graft-forming culture.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 17, 2020
    Applicants: OSAKA UNIVERSITY, TERUMO KABUSHIKI KAISHA
    Inventors: Yoshiki Sawa, Shigeru Miyagawa, Kenji Oyama, Fumiya Ohashi
  • Publication number: 20200360391
    Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.
    Type: Application
    Filed: June 1, 2020
    Publication date: November 19, 2020
    Applicants: Osaka University, Cardio Incorporated
    Inventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi
  • Patent number: 10696948
    Abstract: The present invention provides a method for preparing a clinically applicable, safe and less damaged cardiomyocyte population through a brief and simple procedure from a cell population obtained by induced differentiation of pluripotent stem cells into cardiomyocytes. The present invention relates to a method for preparing a cardiomyocyte population, the method comprising the steps of: (1) inducing pluripotent stem cells to differentiate into cardiomyocytes, (2) bringing a cell population obtained by the induced differentiation into contact with a laminin selected from the group consisting of laminin ?2?1?1, laminin ?2?2?1, laminin ?1?1?1 and laminin ?1?2?1, or a fragment thereof having integrin binding activity, and (3) retrieving cells adherent to the laminin or the laminin fragment.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: June 30, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Yukiko Ochi, Kiyotoshi Sekiguchi, Shigeru Miyagawa, Yoshiki Sawa, Antti Markus Siltanen
  • Publication number: 20200171092
    Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.
    Type: Application
    Filed: May 8, 2018
    Publication date: June 4, 2020
    Applicants: OSAKA UNIVERSITY, ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshiki Sawa, Shigeru Miyagawa, Daisuke Kajita, Hayato Kurata, Kotoe Tamada, Hiroyuki Nishida
  • Publication number: 20200109368
    Abstract: A method for preparing differentiation-induced cells from embryoid bodies derived from pluripotent stem cells is provided. The method includes adding a protease to embryoid bodies. The protease disperses the embryoid bodies, and the protease has an enzyme activity in the range from 0.3 to 4.0 recombinant protease activity unit (rPU)/ml.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 9, 2020
    Applicants: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITY
    Inventors: Hiroko ISEOKA, Fumiya OHASHI, Yoshiki SAWA, Shigeru MIYAGAWA
  • Publication number: 20200102541
    Abstract: A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.
    Type: Application
    Filed: December 4, 2019
    Publication date: April 2, 2020
    Applicants: TERUMO KABUSHIKI KAISHA, OSAKA UNIVERSITY
    Inventors: Fumiya OHASHI, Hiroko ISEOKA, Yoshiki SAWA, Shigeru MIYAGAWA
  • Publication number: 20200045955
    Abstract: This composition can be easily added when cryopreserving cells and improves cell viability. 1 volume % of the composition containing 0.01 wt % to 20 wt % of a sophorose lipid is added just before or up to 6 hours before cryopreservation and cells are stored. This composition can improve cryopreservation cell viability as it reduces freezing damage to cells. With this composition, cells can be stored without using DMSO and blood serum. This is a simple and inexpensive storage method as it does not require fine control of the freezing rate during cell cryopreservation.
    Type: Application
    Filed: January 30, 2018
    Publication date: February 13, 2020
    Inventors: Asuka Nogami, Motoki Tatsumi, Nanase Ishii, Mizuyuki Ryu, Yoshihiko Hirata, Yoshiki Sawa, Shigeru Miyagawa, Atsuhiro Saito, Hirotatsu Ohkawara
  • Publication number: 20190343841
    Abstract: The present invention provides a pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure. The pharmaceutical composition for use in treating an intractable heart tissue fibrosis disease accompanied by chronic heart failure comprises, as an active ingredient, at least one member selected from the group consisting of protease inhibitors, thromboxane A2 synthase inhibitors, thromboxane A2 synthase antagonists, phosphodiesterase (PDE) inhibitors, tyrosine kinase inhibitors, HMG-CoA reductase inhibitors, and antifibrotic agents. (The pharmaceutical composition includes biodegradable polymer-encapsulated, long-acting preparations thereof.
    Type: Application
    Filed: December 27, 2017
    Publication date: November 14, 2019
    Applicants: Osaka University, Cardio Incorporated
    Inventors: Yoshiki Sawa, Shigeru Miyagawa, Yoshiki Sakai, Yasuhiro Yanagi